US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Phase I/II data boosts Coegin Pharma

The first readout from Coegin Pharma’s COAK phase I/II study in actinic keratosis has produced positive results. The top-line data indicates excellent safety and tolerance of AVX001 in 60 patients evaluated with two different doses. BioStock reached out to Coegin’s CEO Tore Duvold to get his perspective on the data.Read the interview with Coegin's CEO Tore Duvold at biostock.se: https://www.biostock.se/en/2022/04/phase-i-ii-data-boosts-coegin-pharma/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Coegin Pharma seeks new opportunities through merger

Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseae, is grabbing the opportunity to strengthen its drug development portfolio by putting strong focus on diabetes complications. BioStock was able to get in touch with Professors Anna Hultgårdh and Jan Nilsson, two internationally-recognised experts in diabetes complications to learn more about what the

BioStock: Coegin Pharma aims high in 2022

In 2021, Coegin Pharma reached a key milestone by launching a combined phase I/II clinical trial with AVX001 in actinic keratosis patients. Moreover, the company expanded its pipeline in order to pursue cancer indications and chronic kidney disease. BioStock reached out to Coegin’s CEO Tore Duvold to hear what he had to say about the company’s achievements during 2021 and his goals for 2022.Read the interview with Tore Duvold at biostock.se: https://www.biostock.se/en/2022/01/coegin-pharma-aims-high-in-2022/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Coegin Pharma takes key steps for growth during Q3

Q3 was an active quarter for Coegin Pharma and its pursuit to address a large unmet medical need in cancer and chronic inflammatory diseases. Highlighted in the company’s interim report are the initiation of the COAK study with AVX001 gel in actinic keratosis patients, the merger with Swedish biotech Follicum, and the development of a new candidate for the treatment of leukaemia and potentially other cancers.Read the full article at biostock.se: https://www.biostock.se/en/2021/11/coegin-pharma-takes-key-steps-for-growth-during-q3/ This is a press release from BioStock - Connecting

BioStock: Coegin Pharma receives final approval for COAK Study

After complying with the conditions given by the Danish Ethics committee in September, Nordic biotech Coegin Pharma has received the final approval for initiating the phase I/II COAK study in actinic keratosis patients. From the beginning of November, the company will begin patient recruitment, and thus take an important step towards developing a novel treatment for a disease with a large unmet medical need.Read the full article at biostock.se: https://www.biostock.se/en/2021/10/coegin-pharma-receives-final-approval-for-coak-study/ This is a press release from BioStock - Connecting

BioStock: Coegin Pharma fuses with Swedish biotech Follicum

Soon after receiving the green light from the Danish Medicines Agency for initiating the phase I/II COAK study in actinic keratosis, Nordic biotech Coegin Pharma reveals new plans for growth and expansion through a merger with Swedish biotech Follicum. BioStock spoke with Coegin’s CEO Tore Duvold to learn the details of the merger and the future implications for the company.Read the interview with Tore Duvold at biostock.se: https://www.biostock.se/en/2021/09/coegin-pharma-fuses-with-swedish-biotech-follicum/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Coegin Pharma on the cusp of initiating COAK Study

Nordic biotech Coegin Pharma reached a key milestone this summer by receiving the green light from the Danish Medicines Agency to begin the Copenhagen Actinic Keratosis Study with lead candidate AVX001. Now, the company has also received a conditional approval from the Ethics Committee, meaning that the clinical trial will be initiated after making slight adjustments to patient information material. BioStock spoke with Coegin’s CEO Tore Duvold to discuss what this all means.Read the interview with Tore Duvold at biostock.se: https://www.biostock.se/en/2021/09/coegin-pharma-on-the-cusp-of-

BioStock: Coegin Pharma’s journey from concept to the clinic

Thirty years of pioneering research led by Professor Berit Johansen at the Norwegian University of Science and Technology aimed at identifying the pro-inflammatory roles and signalling cascades of the cPLA2α enzyme have given rise to Coegin Pharma, a Nordic biotech company ready to take its lead candidate AVX001 to the clinic. Here, BioStock takes a closer look at this journey from concept to clinical development, and how Professor Johansen was able to bring her vision to fruition.Read the full interview with Professor Berit Johansen at biostock.se: https://www.biostock.se/en/coegin-

BioStock: Coegin Pharma - generating value and reducing risk in 2021

With the release of their annual report, Coegin Pharma puts into perspective its main goal of developing a better treatment alternative for cancerous as well as pre-cancerous indications like actinic keratosis. With this goal in mind, the company will be focused on building value and reducing risk for its shareholders in 2021.Read the full article at biostock.se: https://www.biostock.se/en/coegin-pharma-generating-value-and-reducing-risk-in-2021/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Coegin Pharma takes advantage of decentralised clinical trials

Traditional clinical trials can be lengthy and are often a burden for patients involved. Patient recruitment is a major contributor to study delays and, thus, dragged-out drug development timelines. In response, we are seeing the rise of decentralised clinical trials (DCTs) – clinical trials that offer effective digital patient recruitment through digitalisation and a smooth journey for the patients throughout the study period. Coegin Pharma is a prime example of a pharma company taking advantage of DCTs through its collaboration with Studies&Me, an innovative virtual contract research

BioStock: Coegin Pharma applies for clinical study application

There is a high demand for new innovative treatments against the precancerous skin condition actinic keratosis (AK). In the Nordics, Coegin Pharma is developing a drug targeting the cPLA₂α enzyme, which is involved in several inflammatory diseases, cancers and pre-cancerous conditions like AK. This week, the company submitted an application to the Danish Medicines Agency to begin a clinical trial with the drug candidate AVX001.Read the full article at biostock.se: https://www.biostock.se/en/coegin-pharma-applies-for-clinical-study-application/This is a press release from BioStock -

BioStock: Coegin Pharma’s clinical development in actinic keratosis

Actinic keratosis (AK) is one of the most common skin disorders and can be a first step in the development of skin cancer. Patients undergoing conventional AK treatments frequently experience pain, bleeding, inflammation, and scarring. Consequently, new and better treatment options to reduce patient side effects such as skin damage are high demand. The Nordic biotech Coegin Pharma will soon start clinical evaluation of its candidate AVX001 as a potential new and better treatment of AK. BioStock was able to speak with the lead clinician in the clinical program, Professor Merete Hædersdal, to

BioStock: Coegin Pharma brings new vision for cancer treatment

The Nordic biotech Coegin Pharma is responding to calls for new cancer therapeutics by offering a novel approach to cancer treatment through the inhibition of a unique and well- validated target, the cPLA2α enzyme. BioStock got in touch with CEO Tore Duvold to learn more about the company and its strategy for bringing new treatments to cancer patients.Read the full interview with Coegin Pharma's CEO Tore Duvold at biostock.se: https://www.biostock.se/en/coegin-pharma-brings-new-vision-for-cancer-treatment/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

BioStock: Status report Coegin Pharma – A new approach to cancer therapy

Nordic biotech Coegin Pharma is responding to calls for new, innovative cancer therapeutics by offering a novel approach through inhibition of a well-validated target, the cPLA₂α enzyme. Since October 2020, the company has been listed on NGM Nordic SME, and, with an experienced board and management team, Coegin Pharma is executing on its new strategic focus on cancer treatments. BioStock has now published a status report of the company, which can be downloaded below.Read the full status report on Coegin Pharma at biostock.se: https://www.biostock.se/en/status-report-coegin-pharma-a-new-

There are no items matching the current filter
There are no more items matching the current filter
Back to top